Completed PHASE4 INTERVENTIONAL 2-arm NCT05095922

Effect of HMP on Diabetic Microangiopaemia in T2DM

Effect of Heart-Protecting Musk Pill on Diabetic Microangiopaemia in Type 2 Diabetes Patients

Sponsor: Affiliated Hospital of Nantong University

Conditions Diabetes Mellitus, Type 2 Diabetic Angiopathies

Interventions Calcium Dobesilate Capsules Heart-Protecting Musk Pill Valsartan Capsules

Updated 9 times since 2021 Last updated: Jul 8, 2024 Started: Mar 28, 2023 Primary completion: May 30, 2024 Completion: May 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05095922, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and Diabetic Angiopathies and remains completed. Sponsored by Affiliated Hospital of Nantong University, it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Aug 2024 — Sep 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE4
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE4
Jul 2023 — Jun 2024 [monthly]

Recruiting PHASE4

▶ Show 4 earlier versions

Mar 2023 — Jul 2023 [monthly]

Recruiting PHASE4
Sep 2022 — Mar 2023 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jan 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE4
Nov 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiliated Hospital of Nantong University

Data source: Affiliated Hospital of Nantong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nantong, China